Solventum (NYSE:SOLV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Solventum (NYSE:SOLV) from a hold rating to a buy rating in a research report released on Saturday morning,Wall Street Zen reports.

Several other research analysts have also recently issued reports on SOLV. Wedbush upped their target price on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Mizuho set a $113.00 price target on shares of Solventum in a research report on Thursday, August 6th. KeyCorp boosted their price target on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, BTIG Research upped their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $92.80.

Solventum Price Performance

SOLV stock opened at $89.87 on Friday. The business has a 50 day moving average price of $85.39 and a 200 day moving average price of $76.69. The stock has a market cap of $15.30 billion, a price-to-earnings ratio of 10.99, a PEG ratio of 1.36 and a beta of 0.61. Solventum has a fifty-two week low of $62.38 and a fifty-two week high of $94.16. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts anticipate that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SOLV. Independent Franchise Partners LLP increased its position in Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Solventum by 5,434.1% in the 2nd quarter. California State Teachers Retirement System now owns 13,234,928 shares of the company’s stock valued at $1,021,075,000 after buying an additional 12,995,776 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Solventum by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares during the period. Diamond Hill Capital Management Inc. boosted its stake in shares of Solventum by 152.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares in the last quarter. Finally, Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum in the second quarter valued at approximately $150,066,000.

About Solventum

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.